A Study to Observe Vedolizumab and Anti-tumour Necrosis Factors (Anti-TNFs) Outcomes in Real-world Biologic Ulcerative Colitis (UC) and Crohn's Disease (CD) Participants

CompletedOBSERVATIONAL
Enrollment

409

Participants

Timeline

Start Date

February 19, 2019

Primary Completion Date

August 23, 2021

Study Completion Date

February 21, 2022

Conditions
Colitis, UlcerativeCrohn Disease
Trial Locations (26)

17007

Hospital Universitari de Girona Doctor Josep Trueta, Girona

24071

Hospital Universitario de Leon, León

28006

Hospital de La Princesa, Madrid

28007

Hospital General Universitario Gregorio Maranon, Madrid

28040

Hospital Clinico San Carlos, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

28046

Hospital Universitario de La Paz, Madrid

28222

Hospital Universitario Puerta de Hierro, Madrid

31008

Hospital de Navarra, Pamplona

33011

Hospital Universitario Central de Asturias (HUCA), Oviedo

37007

Hospital Universitario de Salamanca, Salamanca

38320

Hospital Universitario de Canarias, Santa Cruz de Tenerife

46010

Hospital Clinico Universitario de Valencia, Valencia

46026

Hospital Universitario y Politecnico La Fe, Valencia

46940

Hospital de Manises, Valencia

4520-211

Centro Hospitalar de Entre Douro e Vouga, Santa Maria da Feira

2674-514

Hospital Beatriz Angelo, Loures

7000-811

Hospital do Espirito Santo de Evora, Evora

1649-028

Centro Hospitalar Universitario Lisboa Norte - Hospital de Santa Maria, Lisbon

2005-177

Hospital Distrital de Santarem, Santarém

07120

Hospital Universitari Son Espases, Palma

08035

Hospital Vall d'Hebron, Barcelona

08041

Hospital de la Santa Creu i Sant Pau, Barcelona

08208

Hospital Universitari Parc Tauli, Barcelona

08970

Hospital de Sant Joan Despi - Moises Broggi, Barcelona

03010

Hospital General Universitario de Alicante, Alicante

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY